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The downstream signaling regulating this is complex, and IL-6-regulated fatty acid oxidation seems to depend on only AMPK (1, 8) , whereas glucose uptake depends on both AMPK and Akt (1, 8) . CNTF-regulated fatty acid oxidation appears also to depend on AMPK (44) , but CNTF-stimulated glucose transport is dependent only on Akt and not AMPK (41) . In addition, CNTF has been shown to have a direct effect on blood glucose levels in mice (41) .
LIF has traditionally been viewed as a cytokine effecting growth promotion and cell differentiation of several target tissues and has in rodents been shown to aid in blastocyst implementation and muscle regeneration and to modulate growth and development of peripheral nerves after injury (27) . LIF has also been shown to have anti-inflammatory properties and to reduce food intake of both monkeys and rodents, similarly to CNTF (3, 19, 44) .
LIF initiates intracellular signaling by binding to a heterodimeric transmembrane receptor complex consisting of the gp130 receptor and LIF receptor ␤-subunits (10) . Upon LIF binding, Janus kinases (JAK), which are constitutively associated to the intracellular part of the receptor complex, become activated by autophosphorylation (16) . JAK phosphorylates specific tyrosine residues on the intracellular part of the receptor complex, thereby creating docking sites for Scr homology 2 (SH2)-containing proteins (10, 11, 15) . This leads to docking and activation of signal transducer and activator of transcription (STAT)3 as well as association of PI 3-kinase to the receptor complex (10) .
Although metabolic actions of CNTF and IL-6 in skeletal muscle have been described, it is unknown whether LIF has similar effects on skeletal muscle metabolism and, if so, the mechanisms involved. Since CNTF (44) and 34) are effective in reversing obesity-related insulin resistance, the purpose of the present study was to describe the metabolic role of LIF in skeletal muscle from lean and obese mice. Our findings show that LIF increases glucose uptake in highly oxidative (soleus) and more glycolytic (extensor digitorum longus, EDL) muscles from mice by a mechanism likely depending on the PI 3-kinase pathway and mechanistic target of rapamycin complex 2 (mTORC2), but not STAT3 or AMPK. In addition, we found that LIF did not increase palmitate oxidation, indicating that metabolic actions of LIF on muscle metabolism are in some respects different compared with IL-6 and CNTF. Interestingly, we also found that whereas LIF-stimulated glucose uptake was suppressed in soleus muscle with high-fat feeding, it was normal in EDL muscle under the same conditions, suggesting an alternative means to enhance glucose uptake in muscle under insulin resistant conditions.
RESEARCH DESIGN AND METHODS
Animals. Male C57Bl/6 mice aged 8 wk were obtained from Taconic Europe. Mice overexpressing the kinase dead (KD) AMPK␣2 subunit under control of the muscle creatine kinase promoter have been described previously (28) . Briefly, expression of the inactive kinase dead ␣2 protein (Lys 45 Arg) displaces all detectable endogenous ␣2 and 50 -70% of endogenous ␣1 protein (20, 28) . Animals used were of the C57Bl/6 strain (Taconic) and 8-to 10-wk-old suppressor of cytokine signaling (SOCS)3 muscle-specific knockout (MKO) mice have been described previously (21) . Briefly, SOCS3 MKO mice were generated by crossing C57Bl/6 SOCS3 floxed mice (24) with C57Bl/6 mice expressing Cre-recombinase under the control of the creatine kinase promoter (7) . Littermates were used as controls in both cases.
Mice were maintained on a 12:12-h light-dark cycle and provided ad libitum access to food and water. Mice received a standard rodent low-fat chow diet (5% calories fat; Altromin no. 1324, Chr. Pedersen, Ringsted, Denmark) except in high-fat diet experiments, where 45% of the energy originated from fat (Research Diets, D12451). All experiments were approved by the McMaster University Animal Ethics Committee or the Danish Animal Experiments Inspectorate and complied with the European Convention.
Glucose tolerance test. A glucose tolerance test was performed after 10 wk of high-fat feeding. Mice were fasted for 6 h before intraperitoneal (ip) injection with a bolus of 1 g glucose/kg body wt using a 30% (wt/vol) glucose solution in 0.9% (wt/vol) saline. Tail blood glucose was monitored over 120 min.
Muscle incubations. For 2-deoxyglucose uptake (2-DG) experiments, soleus (ϳ80% oxidative type I ϩ IIA fibers) and extensor digitorum longus (EDL; ϳ80% glycolytic type IIx ϩ IIB) (4) muscles were dissected from anesthetized mice (6 mg pentobarbital sodium/100 g body wt) and transferred to incubation flasks containing 2 ml of essential buffer (Krebs-Henseleit buffer, pH 7.5, with 2.0 mM pyruvate, 8 mM mannitol, and 0.1% BSA), where they were allowed to remain flaccid, pregassed with 95% O 2 ϩ 5% CO2 (and gassed at every buffer change), and maintained at 30°C, as described (22, 41) . For all experiments, muscles were preincubated for 15 min in essential buffer before being replaced with a similar buffer with or without LIF (Abcam UK) at concentrations and durations as indicated. In separate experiments, muscles were incubated with 500 nM wortmannin (Sigma-Aldrich, St. Louis, MO), 60 nM LY-294002 hydrochloride (Sigma-Aldrich), 25 M parthenolide (Sigma-Aldrich), 1 mM rapamycin (Sigma-Aldrich), or 1.28 mM AZD8055 (Selleckchem, Houston, TX) for 30 min before treatment with LIF. 2-DG uptake was measured for 10 min by replacing the existing incubation buffer with similar buffers in addition containing 0.5 Ci/ml 2-deoxy-D- [2,6- 3 H]glucose, 1 mM 2-deoxy-D-glucose, and 0.5 Ci/ml [1- 14 C]mannitol/ml. After preparation of muscles as described below, radioactivity was measured in muscle lysates by liquid scintillation counting (TriCarb 2910, PerkinElmer, Waltham, MA).
For palmitate oxidation experiments, soleus muscles were dissected as described and transferred to incubation flasks containing 2 ml of basal buffer [Krebs-Henseleit buffer, pH 7.5, with 2.0 mM pyruvate, 4% BSA, and 1 mM palmitic acid (Sigma-Aldrich)] gassed with 95% O 2 ϩ 5% CO2, and maintained at 30°C, as described (40) . For all experiments, muscles were preincubated for 15 min in basal buffer before being replaced with a similar buffer containing vehicle, 5,000 pM (100 ng/ml) LIF (Abcam) or 4,546 pM (100 ng/ml) axokine ciliary neurotrophic factor (kind gift from Mark W. Sleeman, Regeneron Pharmaceuticals, New York, NY) as well as 0.5 Ci/ml [1-14C]palmitate/ml (Sigma-Aldrich) for 60 min. Radioactivity was measured in the CO2 fraction after benzethonium hydroxide capture, and in the acid-soluble metabolite fraction after chloroform-methanol extraction (40) .
Muscle homogenization. Muscles were homogenized in ice-cold buffer containing 50 mM HEPES, pH 7.4, 150 mM NaCl, 100 mM NaF, 10 mM sodium pyrophosphate, 5 mM EDTA, 250 mM sucrose, 1 mM dithiothreitol, 1% Triton X-100, 1 mM Na 3VO4, and one Roche protease inhibitor tablet/50 ml using a TissueLyser II (Qiagen, Hilden, Germany). Homogenates were rotated end over end for 1 h at 4°C before centrifugation for 30 min (17,500 g, 4°C). Lysates were snap-frozen in liquid nitrogen and stored at Ϫ80°C. Protein content was measured by the bicinchoninic acid method (Pierce, Rockford, IL).
Immunoblotting. Expression and phosphorylation of relevant proteins were determined in muscle lysates by SDS-PAGE followed by immunoblotting. (1:1,000) was measured using phosphospecific antibodies from Cell Signaling Technology (Beverly, MA). Total Akt2 (1:1,000), STAT3 (1:2,000), ERK1/2 (1:1,000), and NDRG1 (1:500) protein levels were measured using antibodies from Cell Signaling Technology, and phosphorylation of Akt Thr 308 (1:1,000) was measured using an antibody from Upstate Biotechnology (Lake Placid, NY). Total AS160 (1:1,000) protein levels were measured using an antibody from Millipore (Darmstadt, Germany), and AMPK␣2 (1:15,000) was measured using an antibody kindly donated by D. G. Hardie (University of Dundee, Dundee, Scotland, UK).
Characterization of recombinant LIF protein. The quality of recombinant human LIF (L5283; Sigma-Aldrich) was verified by UHPLC-ESI-Mass Spectrometry (Dionex, Bruker Daltronics), for verification of molecular weight, nonreducing SDS-PAGE Coomassie blue staining (see Fig. 7 ), and kinetic turbidimetric LAL assay for endotoxin content. The average mass was measured to 19,679.84 kDa, and the endotoxin analysis showed an endotoxin level of 12 EU/mg (ϳ50 nmol), which is considered low.
Statistics. Data are expressed as means Ϯ SE. Statistical evaluations were performed by one-or two-way ANOVA for main effects of treatments and genotype followed by a Bonferroni test for post hoc comparisons, with significant differences at P Ͻ 0.05.
RESULTS

Dose dependencies of LIF-stimulated muscle glucose uptake and signaling.
To test the effects of LIF on skeletal muscle glucose uptake, isolated SOL and EDL muscles were incubated with LIF at concentrations ranging from 50 to 5,000 pM for 30 min. LIF increased muscle glucose uptake in SOL in a dosedependent manner, with a significant increase starting at 500 pM and a maximal increase of ϳ90% at 5,000 pM (Fig. 1A) . In EDL muscle, glucose uptake was increased by ϳ70% at 5,000 pM. Activation of gp130 receptor complexes increase PI 3-kinase/Akt, AMPK, STAT3, and ERK signaling (10, 15) ; hence, we measured activating phosphorylation of these molecules. 5,000 pM of LIF increased pAkt Ser 473 by ϳ260% in soleus and EDL (Fig. 1B) . Akt Thr 308 P was not affected by LIF treatment in SOL and was below detection limit in EDL (Fig.  1C) . To further investigate the role of Akt signaling, we investigated AS160 phosphorylation (PAS), a downstream target of Akt signaling. Interestingly, AS160 PAS was not affected by LIF treatment in either SOL or EDL (Fig. 1D ). Other cytokines from the IL-6 family have been shown to activate AMPK by increasing Thr 172 P (1, 8, 41, 44) , but LIF did not increase AMPK Thr 172 P in either muscle type (Fig. 1E ). 5,000 pM LIF increased STAT3 Tyr 705 P by ϳ90% and ERK phosphorylation by ϳ18% in SOL, whereas it was not statistically increased in EDL (Fig. 1, F and G) .
Time course of LIF-stimulated muscle glucose uptake and signaling. The maximal effect of LIF on glucose uptake in both muscle types was observed after 30 min. However, it cannot be ruled out that the maximal effects had occurred before 30 min. There were no significant increases compared with basal at 60 and 90 min ( Fig. 2A) . Changes in glucose uptake with time were mirrored by Akt Ser 473 P (Fig. 2B ), but not STAT3 Tyr 705 P, which was activated in Fig. 1 . Dose-dependent effect of leukemia inhibitory factor (LIF) on glucose uptake and signaling in incubated soleus (SOL; left) and extensor digitorum longus (EDL; right) at basal (BAS) conditions and after incubation with LIF at indicated concentrations or 10.000 U/ml insulin for 30 min. LIF and insulin-stimulated glucose uptake (A). LIF-stimulated Akt Ser 473 phosphorylation (p) relative to total Akt2 protein content (B), Akt Thr 308 P relative to total Akt2 protein content (C), AS160 PAS P relative to total AS160 (D), AMPK Thr 172 P relative to total AMPK protein content (E), STAT3 Tyr 705 P relative to total STAT3 protein content (F), and ERK1/2 Thr 202/185 /Tyr 204/187 P relative to total ERK1/2 protein content (G). Representative blots of the presented signaling molecules (H). Values are expressed as means Ϯ SE; n ϭ 6 -8 (insulin incubations n ϭ 2). *P Ͻ 0.05 vs. basal, **P Ͻ 0.01 vs. basal. EDL at later time points (Fig. 2C ). In agreement with the dose-response study, LIF did not affect Akt Thr 308 P or AMPK Thr 172 P at any of the investigated time points, and pERK was not affected either (data not shown).
Effects of PI 3-kinase and JAK inhibitors on LIF actions.
To further investigate the importance of PI 3-kinase in LIFstimulated glucose uptake, muscles were preincubated with the PI 3-kinase inhibitors wortmannin and LY-294002, followed by stimulation with 5,000 pM LIF for 30 min. Preincubation with LY-294002 and wortmannin (data not shown) completely inhibited LIF-stimulated glucose uptake in both muscle types (Fig. 3A) , and LY-294002 also inhibited basal glucose uptake (Fig. 3A) . To assess the importance of JAK/STAT signaling, muscles were preincubated with parthenolide, an inhibitor reported to block JAK-dependent STAT activation (38) . Parthenolide also completely blocked LIF-stimulated glucose uptake in both soleus and EDL (Fig. 3A) but did not affect the basal glucose uptake.
LIF increased pAkt Ser 473 by 200 -600% in the two muscle types (Fig. 3B) . LY-294002 and wortmannin (data not shown) abolished basal and LIF-stimulated Akt Ser 473 P. Parthenolide suppressed LIF-stimulated increases in Akt Ser 473 P in SOL but not in EDL (Fig. 3B) .
LIF increased STAT3 Tyr 705 P by ϳ50 -90% and ϳ200 -300% in SOL and EDL, respectively (Fig. 3C) . LY-294002 did not impair LIF-stimulated STAT3 Tyr 705 P in either muscle type, whereas wortmannin surprisingly abolished this response in SOL and reduced it by ϳ50% in EDL (data not shown), suggesting nonspecific actions of wortmannin. As anticipated, parthenolide abolished LIF-induced increases in pSTAT3 Tyr 705 in SOL and suppressed both basal and LIF-stimulated increase in STAT3 Tyr 705 P in EDL (Fig. 3C ). These observations suggest that both PI 3-kinase and JAK inhibitors impair LIF regulation of glucose uptake in skeletal muscle.
Effect of ablated AMPK activity on LIF actions. To examine the importance of AMPK signaling in LIF-mediated glucose uptake, muscles from wild-type and AMPK␣2 kinase dead (KD) mice were incubated with 5,000 pM LIF for 30 min. LIF treatment increased glucose uptake, Akt Ser 473 P and STAT3 Tyr 705 P to a similar extent in WT and AMPK KD mice, although there was a trend (P ϭ 0.093) toward reduced glucose uptake in SOL. This suggests that the effect of LIF is independent of AMPK (Fig. 4, A-D) . Effect of mTORC inhibition on LIF actions. Because LIF increased Akt Ser 473 P, we speculated that mTORC2 might be involved, since this molecule has been described as the Akt Ser 473 kinase (36) . We investigated the importance of mTORC signaling on LIF-mediated glucose uptake in the most LIFresponsive muscle (SOL) using relevant inhibitors. To distinguish signaling via mTORC1 and mTORC2, SOL muscles were preincubated with or without the specific mTORC1 inhibitor rapamycin (35) and the inhibitor of both mTORC1 and -2, AZD8055 (9), followed by stimulation with 5,000 pM LIF for 30 min. Preincubation with rapamycin did not affect LIF- stimulated glucose uptake, whereas AZD8055 reduced both basal and LIF-stimulated glucose uptake (Fig. 5A) .
The ϳ100% increased pAkt Ser 473 with LIF was unaffected by rapamycin but completely inhibited by AZD8055 (Fig. 5B) . Neither LIF nor rapamycin affected Akt Thr 308 P, whereas AZD8055 blocked basal Akt Thr 308 P (Fig. 5C ). The ϳ50% increase in STAT3 Tyr 705 P with LIF was not affected by either rapamycin or AZD8055 (Fig. 5D) . LIF increased phosphorylation of the mTORC2 target N-myc downstream regulated 1 (NDRG1) at Thr 346 by ϳ90% (Fig. 5E) , which, as expected, was not affected by rapamycin (Fig. 5E ). Moreover, AZD8055 completely blocked both basal and LIF-stimulated NDRG1 Thr 346 P (Fig. 5E ). These observations suggest that inhibition of mTORC2 signaling may impair LIF regulation of glucose uptake in soleus muscle.
LIF-stimulated glucose uptake in SOCS3 MKO mice. The SOCS3 protein is a negative feedback regulator of gp130 receptor signaling (33, 39) . We therefore hypothesized that upregulation of SOCS3 with ligand-induced STAT3 activation could explain the downregulation of LIF-induced glu- cose uptake observed in the time course study at the 90-min time point despite continuous LIF exposure. We incubated SOL muscles from WT and SOCS3 MKO mice with 100 ng/ml LIF for 30 or 90 min. As expected, in WT muscle LIF increased glucose uptake after 30 min, and this increase was substantially suppressed after 90 min (Fig. 5G) . Surprisingly, the same changes were also observed in SOCS3 MKO muscle, suggesting that SOCS3 is not essential for inhibiting LIF-receptor signaling.
Effects of LIF on palmitate oxidation. CNTF has previously been shown to increase fatty acid oxidation in skeletal muscle by activating AMPK (44) . To investigate whether LIF also regulates muscle lipid oxidation, we measured the ability of LIF to stimulate palmitate oxidation in mouse soleus muscles ex vivo. In contrast to the effects of CNTF, which increased palmitate oxidation by 20%, LIF did not alter palmitate oxidation (Fig. 5H) .
Effects of obesity on LIF-stimulated glucose uptake and signaling. It is well known that obesity is associated with impaired insulin sensitivity in skeletal muscle, and several studies have linked this to impaired IRS-1 and PI 3-kinase signaling and enhanced phosphatase 2A (PP2A)-dependent Akt dephosphorylation (17, 37, 42, 47) . We investigated whether LIF-stimulated glucose uptake was maintained in mice fed a high-fat (HF) diet for 12 wk. As expected, HF feeding increased body weight (ϳ20%) and epididymal fat pad weight (ϳ400%) (Fig. 6A) as well as development of glucose intolerance (Fig. 6B ) compared with chow-fed animals. LIF increased glucose uptake by ϳ100% in SOL and ϳ35% in EDL muscle from chow-fed animals. Interestingly, LIF-stimulated glucose uptake was reduced by ϳ60% in SOL and was normal in EDL muscle from HF-fed animals (Fig. 6C) . We have previously shown (41) that the same diet intervention impairs CNTFstimulated Akt phosphorylation in mouse muscle; however, HF feeding did not impair LIF increased pAkt Ser 473 in either of the two muscle types (Fig. 6D) despite impaired LIF-stimulated glucose uptake in the SOL.
DISCUSSION
Cytokines of the IL-6 family are reported to be involved in multiple inflammatory responses in various tissues (14, 27, 43, 46) , but more recent studies have shown that several members also have acute actions on muscle metabolism (8, 13, 41, 44, 45) . LIF serum levels are low in healthy individuals and elevated only in patients with severe inflammatory conditions (usually Ͻ50 pM) (31) . Like most cytokines, LIF production is highly inducible and can be expressed in a broad range of cell types. Recent studies of human skeletal muscles reported that LIF mRNA increases with exercise (6) and that both the LIF receptor and LIF protein levels are higher in muscle from type 2 diabetics compared with matched normoglycemic individuals (5). Both IL-6 and CNTF have been shown to increase muscle glucose uptake and regulate whole body glucose homeostasis (8, 13, 41, 44, 45) , and LIF has been shown to increase glucose uptake in cardiomyocytes (12) , but it is, to the best of our knowledge, not known whether LIF increases glucose transport of skeletal muscle.
In recent years, there has been increased focus on the lack of reproducibility of published scientific findings (2) where, for example, quality or contamination are inherent risks when working with recombinant proteins. We therefore employed a QC evaluation, which confirmed the molecular weight, showed no indications of contamination or degradation products, and showed low endotoxin levels. Thus, this suggested that the observed responses are related to LIF and not unknown factors, e.g., generated during protein production.
The aim of this study was to investigate the effects of LIF on glucose uptake and lipid oxidation in skeletal muscle and to investigate potential signaling pathways involved. The present study shows that LIF stimulates glucose uptake in skeletal muscle, and it describes potential proximal signaling events in muscle leading to this response. We show that LIF increases glucose uptake ex vivo, and data based on the use of inhibitors may suggest that the PI 3-kinase/mTORC2/Akt signaling pathway could play at least a permissive role. An additional finding was that LIF did not regulate palmitate oxidation, which was surprising, as both IL-6 and CNTF enhanced muscle lipid metabolism. We also tested whether the efficacy of LIF to stimulate glucose uptake was impaired in muscles from obese insulin-resistant mice and found that whereas soleus became somewhat LIF resistant, LIF sensitivity was maintained in EDL with obesity.
We hypothesized that JAK-dependent receptor activation and PI 3-kinase were necessary signaling components in LIFstimulated glucose uptake (41) . Inhibition of JAK with parthenolide suppressed glucose uptake and STAT3 and Akt signaling, indicating reliance on JAK-dependent gp130 and LIF receptor phosphorylation and activation. Furthermore, using two different classes of PI 3-kinase inhibitors, LY-294002 and wortmannin, we found a complete or almost complete ablation of LIF-stimulated Akt Ser 473 P and glucose uptake in both muscle types, suggesting a significant role of the PI 3-kinase. However, as LY-294002 also inhibited basal glucose uptake, the role of PI 3-kinase could be permissive rather than directly involved as a signaling molecule. Furthermore, observations based on inhibitors are seldom conclusive due to potential off-target actions, but the finding that both LY-294002 and wortmannin impair LIF action does strengthen the idea that PI 3-kinase is involved. In contrast, studies of cardiomyocytes showed that wortmannin did not impair LIF-stimulated glucose uptake (12) , indicating that LIF regulates glucose uptake by two different mechanisms in cardiomyocytes and skeletal muscle. Incubation with LIF resulted in a selective increase in Akt Ser 473 P without detectable changes in Thr 308 P, suggesting that LIF signaling at the level of Akt is independent of Thr 308 P. The lack of a detectable increase in Akt Thr 308 P was reproducible between independent experiments using an antibody verified using insulin-stimulated muscle. In addition, phosphorylation of AS160, a downstream target of Akt, was also unaffected by incubation with LIF. The transient increase in glucose uptake with LIF in both EDL and soleus was mirrored by an increase in Akt Ser 473 P, supporting the idea that PI 3-kinase/Akt signaling is involved in this regulation. PI 3-kinase contributes to Akt activation by phosphorylating PIP2 to form PIP3, which facilitates correct membrane positioning of Akt for activating phosphorylation by mTORC2 at Ser 473 and phosphoinositide-dependent kinase-1 (PDK1) at Thr 308 . As we consistently observed that LIF specifically increased Akt Ser 473 , we hypothesized that the Akt Ser 473 kinase mTORC2 would be required for a maintained response in glucose uptake with LIF. We showed that the mTORC1 inhibitor rapamycin (35) did not affect glucose uptake and Akt Ser 473 P, suggesting no significant role of mTORC1. Con- Fig. 7 . Protein characterization. Quality of recombinant human LIF was verified by UHPL-ESI-MS for molecular weight (MW) determination, nonreducing SDS-PAGE for purity, and kinetic LAL assay for endotoxin content.
versely, AZD8055, which is reported to inhibit both mTORC1 and mTORC2 (9) , suppressed basal glucose uptake and basal phosphorylation of both Akt Thr 308 /Ser 473 and the mTORC2 activity readout NDRG1 at Thr 346 . In addition to suppressing basal levels LIF-induced increases were also either blunted or suppressed with AZD8055. Neither of the two inhibitors affected STAT3 Tyr 705 phosphorylation, indicating that proximal LIF signaling was not impaired. In combination, these data suggested that mTORC2-dependent phosphorylation of Akt is required for a normal increase in LIF-induced glucose uptake. Again, caution is warranted when concluding on data obtained using inhibitors due to the risk of off-target effects, but the data do indicate that the PI 3-kinase/mTORC2/Akt pathway is involved in LIF-stimulated glucose uptake of mouse skeletal muscle at some level.
AMPK is a well-characterized regulator of glucose uptake and lipid oxidation (1, 8, 26, 41, 44) . Studies of cardiomyocytes did not report an increase in AMPK phosphorylation with LIF (12), whereas both CNTF and IL-6 have been shown to activate AMPK in skeletal muscle (8, 13, 23, 41, 44) ; thus, one may anticipate involvement of additional signaling pathways in skeletal muscle. We therefore investigated whether AMPK had a contributing role in LIF-stimulated glucose uptake. However, we did not detect any activation of AMPK Thr 172 P by LIF, and LIF-stimulated glucose uptake was normal in muscles overexpressing KD AMPK␣2, suggesting that LIF does not activate AMPK and AMPK is not involved in LIF-stimulated glucose uptake in muscle. This is supported by the finding that LIF did not increase muscle lipid oxidation, in contrast to reports on IL-6 and CNTF (8, 44) showing that different members of the IL-6 family appear to have distinct metabolic actions in skeletal muscle. Also, we observed a downregulation of LIFstimulated glucose uptake and Akt Ser 473 P when exceeding 30 min of LIF exposure, whereby both glucose uptake and Akt Ser 473 P both returned to basal values after 90 min of LIF exposure. gp130 Receptor signaling is under temporal control of negative feedback mechanisms involving the STAT-dependent transcriptional induction of SOCS3 (25) , which has been shown to suppress both gp130 and insulin receptor signaling (33, 39) . However, time-dependent LIF resistance developed to the same degree in SOCS3 MKO muscles as observed in WT muscles. This indicates that SOCS in skeletal muscles are either not responsible for the downregulation of LIF-stimulated glucose uptake or that upregulation of other homologous SOCS isoforms such as SOCS1 perhaps compensated for the lack of SOCS3 (29) .
An additional purpose of the study was to assess if LIFstimulated glucose uptake was impaired by obesity and if LIF could comprise an alternative mechanism to increase muscle glucose uptake during insulin resistance. We tested this hypothesis in muscles from obese glucose-intolerant mice and found that LIF-stimulated glucose uptake was normal in EDL, whereas soleus developed some degree of LIF resistance. These findings are in contrast to our previous finding where we showed that both EDL and soleus developed CNTF resistance, using the same obesity-inducing diet intervention (41) . Interestingly, as LIF-induced Akt Ser 473 P was not impaired with obesity, the development of moderate LIF resistance in the soleus appears to be downstream of proximal signaling.
LIF has been reported to be increased to 40 -50 pM in human blood with infectious diseases, which is 10 times lower than the lowest effective dose used in the current ex vivo study (31) . This may suggest that LIF in vivo does not increase to levels resulting in physiologically relevant regulations of skeletal muscle glucose uptake. However, LIF is one of several IL-6 family molecules known to have the potential to increase muscle glucose uptake (1, 8, 41, 44) , and it could be that these in combination have some effect on skeletal muscle glucose uptake or that LIF increases locally to concentrations affecting muscle glucose uptake. Interestingly, even if the physiological role is minor or only relevant during specific conditions, it could still be that pharmacological levels of LIF could improve glucose homeostasis with diabetes.
In summary, we show that LIF increased glucose uptake twofold in isolated soleus and EDL muscle in a dose-dependent manner. On the basis of the use of inhibitors and isolated muscles, we propose that LIF-stimulated glucose uptake at least to some degree depends on the PI 3-kinase/mTORC2/Akt signaling pathway; however, we cannot rule out that this signaling pathway has a mainly permissive role. Furthermore, in contrast to IL-6 and CNTF, LIF did not increase AMPK phosphorylation and lipid oxidation, illustrating unique metabolic effects. We also showed that the transient time-dependent attenuation of LIF-stimulated glucose uptake occurred normally in muscles deleted of SOCS3, indicating that SOCS3 is not essential in this response. Thus, future research should investigate whether LIF may be able to regulate glucose homeostasis in vivo and provide an alternative strategy to reduce blood glucose with type 2 diabetes.
